1086391-08-3

Usage

Uses

Used in Organic Synthesis:
3-bromo-1H-indazol-5-carbaldehyde is utilized as a key building block in organic synthesis for the creation of various heterocyclic compounds. Its unique structure and reactivity make it a valuable component in the development of new organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-bromo-1H-indazol-5-carbaldehyde is employed as a precursor in the synthesis of potential drug candidates. Its versatility in chemical reactions allows for the exploration of new therapeutic agents.
Used in Antimicrobial Applications:
3-bromo-1H-indazol-5-carbaldehyde has been investigated for its antimicrobial properties, making it a candidate for use in the development of new antimicrobial agents to combat resistant strains of bacteria.
Used in Anticancer Research:
3-broMo-1H-indazol-5-carbaldehyde has also been studied for its potential anticancer properties, indicating its use in the development of novel cancer treatments. Further research is needed to understand its mechanism of action and therapeutic potential in this area.

Upstream product

• 253801-04-6 1H-indazole-5-carbaldehyde 
• 128-08-5 N-Bromosuccinimide 

Downstream Products

• 1548128-53-5 3-bromo-2-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazole-5-carbaldehyde 
• 1351571-43-1 (5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-1H-indazol-5-yl}methylidene)-3-(3S,4S)-(3-fluoro-1-methylpiperidin-4-yl)-1,3-thiazolidine-2,4-dione 
• 1548128-70-6 C₂₉H₂₈ClF₃N₄O₅S 
• 1548128-74-0 C₂₉H₂₈ClF₃N₄O₅S 
• 1351569-83-9 C₁₉H₁₁ClF₃N₃O₂S 
• 1351571-37-3 (5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-1H-indazol-5-yl}methylidene)-3-[(3R,4R)-3-fluoropiperidin-4-yl]-1,3-thiazolidine-2,4-dione 
• 1548129-20-9 C₂₉H₂₇ClF₄N₄O₄S 
• 1548129-12-9 C₂₉H₂₇ClF₄N₄O₄S 
• 1548128-76-2 C₂₉H₂₇ClF₄N₄O₄S 
• 1548129-04-9 (Z)-5-((1-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazol-5-yl)methylene)-3-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)thiazolidine-2,4-dione hydrochloride salt 
• 1351571-42-0 (5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-1H-indazol-5-yl}methylidene)-3-(3R,4R)-(3-fluoro-1-methylpiperidin-4-yl)-1,3-thiazolidine-2,4-dione 
• 1312704-84-9 1-[4-chloro-2-(trifluoromethyl)benzyl]-1H-indazole-5-carbaldehyde 
• 1548128-56-8 C₁₆H₁₂ClF₃N₂O 
• 1428940-06-0 3-bromo-2-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazole-5-carbaldehyde 

Relevant academic research and scientific papers

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Process development for scale-up of a novel 3,5-substituted thiazolidine-2,4-dione compound as a potent inhibitor for estrogen-related receptor 1

The development of a reproducible process for multihundred gram production of (Z)-5-((1-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazol-5-yl)methylene)-3- ((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)thiazolidine-2,4-dione (26), a potent and selective inhibitor of estrogen-related receptor 1 (ERR1), is described. This multihundred gram synthesis was achieved via magnesium perchlorate- catalyzed regioselective epoxide ring-opening of tert-butyl 7-oxa-3- azabicyclo[4.1.0]heptane-3-carboxylate (9) with thiazolidine-2,4-dione (6, TZD) to form a diastereomeric mixture tert-butyl 4-(2,4-dioxothiazolidin-3-yl)-3- hydroxypiperidine-1-carboxylate (17), of which the 3-hydroxyl group was functionally transformed to 3-fluoro derivative 19 after treatment with Deoxo-Fluor. Chiral separation of 19 provided the desired diastereomer (3R,4R)-21 that was converted to the secondary amine 23 TFA salt. Reductive amination of 23 produced the key intermediate N-methyl 24. Knoevenagel condensation of 24 with 1-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazole-5- carbaldehyde (5) produced the final product 26 in 10% overall yield (99.7% HPLC area% with ≥99.5% de) after a convergent eight synthetic steps with the only column purification being the chiral HPLC separation of 3R,4R-21 from 3S,4S-22.

BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF

This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated

ANNELLATED 4- (INDAZOLYL) -1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF

This invention relates to novel annellated 4-(indazolyl)-l,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-